

24. Chin PKL, Wright DFB, Zhang M, et al. Correlation between trough plasma dabigatran concentrations and estimates of glomerular filtration rate based on creatinine and cystatin C. *Drugs R D*. 2014;14(2):113-123.
25. King PK, Stump TA, Walkama AM, et al. Management of Phenobarbital and Apixaban Interaction in Recurrent Cardioembolic Stroke. *Ann Pharmacother*. 2018;52(6):605-606.
26. Dagan G, Perlman A, Hochberg-Klein S, et al. Managing Direct Oral Anticoagulants in Patients With Antiepileptic Medication. *Can J Cardiol*. 2018;34(11):1534e1-1534e3.
27. Eyal S, Lamb JG, Smith-Yockman M, et al. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. *Br J Pharmacol*. 2006;149(3):250-260.
28. Červený L, Švecová L, Anzenbacherová E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. *Drug Metab Dispos*. 2007;35(7): 1032-1041.
29. Olaizola I, Brodde MF, Kehrel BE, Evers S. The Impact of Levetiracetam and Valproate on Platelet Functions-A Double-Blind, Placebo-Controlled Crossover Study. *J Clin Med*. 2023;12(3):933.
30. Langenbruch L, Meuth SG, Wiendl H, et al. Clinically relevant interaction of rivaroxaban and valproic acid – A case report. *Seizure*. 2020;80:46-47.
31. SPC ČR: Depakine Chrono® (kyselina valproová), Sanofi s.r.o., 7/2024. [Internet]. Available from: <https://sukl.gov.cz/verejnost/leciva/>.
32. SPC ČR: Xarelto® (rivaroxaban), Bayer Pharma, 9/2024. [Internet]. Available from: https://www.ema.europa.eu/documents/product-information/xarelto-epar-product-information_cs.pdf.
33. SPC ČR: Keppra (levetiracetam), UCB Pharma 1/2025. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/keppra-epar-product-information_cs.pdf.
34. Mavri A, Ilc S. The efficacy of direct oral anticoagulants in patients on concomitant treatment with levetiracetam. *Sci Rep*. 2023;13(1):9257.
35. Giner-Soriano M, Marsal JR, Gomez-Lumbreras A, et al. Risk of ischaemic stroke associated with antiepileptic drugs: a population-based case-control study in Catalonia. *BMC Neurol*. 2021;21(1):208.
36. Sáez-Torres de Vicente M, Puig PM, Toresano LV, et al. Ischemic stroke due to possible interaction of rivaroxaban with primidone in a patient with atrial fibrillation. *Med Clin (Barc)* 2021;156(5):255-256.
37. Manis MM, Petersen K, Roberts MZ, Kyle JA. Managing the Drug-Drug Interaction With Apixaban and Primidone: A Case report. *Hosp Pharm*. 2023;58(4):345-349.
38. Andreasen A, Brosen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on cyp3a4. *Epilepsia*. 2007; 48(3):490-496.
39. Serra W, Calzi ML, Coruzzi P. Left Atrial Appendage Thrombosis During Therapy with Rivaroxaban in Elective Cardioversion for Permanent Atrial Fibrillation. *Clin Pract*. 2015;5(3):788.
40. Robinson ZS, Arvin JP, Madding KL, et al. Rivaroxaban Failure in a Patient Taking Oxcarbazepine. *Ann Pharmacother*. 2021;55(10):1302-1303.
41. SPC ČR: Diacomit® (spiripentol), Biocodex, 7/2024 https://www.ema.europa.eu/cs/documents/product-information/diacomit-epar-product-information_cs.pdf.
42. Kerr BM, Martinez-Lage JM, Viteri C, et al. Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol. *Epilepsia*. 1991;32(2):267-274.
43. SPC ČR: Fycompa (perampanel), Eisai 5/2023. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/fycompa-epar-product-information_cs.pdf.
44. SPC ČR: Inovelon® (rufinamid), Eisai GmbH, 12/2023. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/inovelon-epar-product-information_cs.pdf.
45. Stölberger C, Finsterer J, Schneider B. Interactions between antiepileptic drugs and direct oral anticoagulants for primary and secondary stroke prevention. *Expert Opin Drug Metab Toxicol*. 2024;20(5):359-376.
46. Greene SA, Kwak C, Kamin M, et al. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects. *Clin Transl Sci*. 2022;15(4):899-911.
47. SPC ČR: Ontozry® (cenobamát), Angelini Pharma, 12/2024. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/ontozry-epar-product-information_cs.pdf.
48. Bansal S, Zamarripa CA, Spindle TR, et al. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants. *Clin Pharmacol Ther*. 2023; 114(3):693-703.
49. SPC ČR: Epidyolex® (kanabidiol), Jazz Pharmaceuticals Ireland. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/epidyolex-epar-product-information_cs.pdf.
50. Martin P, Czerwinski M, Limaye PB, et al. In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions. *Pharmacol Res Perspect*. 2022;10(3):e00959.
51. SPC ČR: Fintepla® (fenfluramin), UCB Pharma 8/2024. [Internet]. Available from: https://www.ema.europa.eu/cs/documents/product-information/fintepla-epar-product-information_cs.pdf.
52. Grymnoprez M, Carnoy L, Capiou A, et al. Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study. *Eur Heart J Cardiovasc Pharmacother*. 2023;9(8):722-730.



FACEBOOK

<https://www.facebook.com/SolenMedicalEducation/>

@SolenMedicalEducation



X

<https://twitter.com/MedicalSolen>

@MedicalSolen



LINKEDIN

<https://www.linkedin.com/company/solen-medical-education/>

#solenmedicaleducation

» ODEMČENÉ **AKTUÁLNÍ ČLÁNKY**

» **PŘEHLED** O VZDĚLÁVACÍCH AKCÍCH

» UPOZORNĚNÍ NA **ZVÝHODNĚNÉ CENY**

» **SOUTĚŽE** O VSTUPENKY NA KONGRESY

» INFORMACE O **ON-LINE** KURZECH

» NOVINKY V **E-SHOPU**

... a mnoho dalšího

... **nenechte si ujít aktuální informace**
o možnostech medicínského vzdělávání